T2 Biosystems, Inc. (TTOO)
- Previous Close
2.9900 - Open
3.0100 - Bid 2.9200 x 100
- Ask 3.0300 x 100
- Day's Range
2.9200 - 3.0700 - 52 Week Range
2.7000 - 70.0000 - Volume
34,102 - Avg. Volume
246,952 - Market Cap (intraday)
16.316M - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-19.1900 - Earnings Date May 21, 2024 - May 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
www.t2biosystems.com113
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TTOO
Performance Overview: TTOO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TTOO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TTOO
Valuation Measures
Market Cap
26.03M
Enterprise Value
59.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.07
Price/Book (mrq)
--
Enterprise Value/Revenue
8.32
Enterprise Value/EBITDA
-1.36
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-85.27%
Return on Equity (ttm)
--
Revenue (ttm)
7.19M
Net Income Avi to Common (ttm)
-50.08M
Diluted EPS (ttm)
-19.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
15.69M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.07M
Research Analysis: TTOO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell